Needham & Company LLC's Rating of CorMedix on 10/19/2026

On October 19, 2026, Needham & Company LLC updated its outlook on CorMedix (NASDAQ:CRMD) with the action "Reiterated Rating", keeping a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Needham & Company LLC

DateCompanyAction
11/18/2026
NIKE, Inc. stock logo
NKE
NIKE
Reiterated Rating
11/18/2026
Biogen Inc. stock logo
BIIB
Biogen
Reiterated Rating
11/18/2026
MP Materials Corp. stock logo
MP
MP Materials
Initiated Coverage
11/18/2026
The Walt Disney Company stock logo
DIS
Walt Disney
Boost Price Target
11/18/2026
NVIDIA Corporation stock logo
NVDA
NVIDIA
Reiterated Rating
11/17/2026
Pulse Biosciences, Inc stock logo
PLSE
Pulse Biosciences
Reiterated Rating
More Ratings From Needham & Company LLC